MCKESSON CORP — Form 8-K
Filed August 5, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
McKesson reported Q1 FY2027 revenues of $105.4B (+8% YoY) with adjusted EPS of $9.93 (+20% YoY). The company raised full-year adjusted EPS guidance to $44.20–$45.00 from $43.80–$44.60 (13–15% growth). Key actions: $2.6B returned to shareholders ($2.25B in accelerated share repurchase, 5% share count reduction); 15% dividend increase to $0.94/share (tenth consecutive year); $1.25B sale of 13% stake in Medical-Surgical Solutions to Apollo Funds on June 1, 2026; $2.25B Term Loan B facility to support planned MSS separation.
Why this rating
Strong operational beat (+20% adjusted EPS) and raised guidance support positive near-term sentiment, but MSS separation execution risk and routine capital deployment limit material trajectory change relative to $95B market cap.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.